Given the current "Safety First" mind-set among regulators, it’s not surprising that the field of predictive toxicology has been slow to gain traction. Despite significant progress in developing biomarkers, database tools, and other methods, pharma companies continue to rely heavily on traditional methods for assessing potential drug toxicities.
Predictive toxicology can be broadly split into two categories. Artificial intelligence systems can match structural characteristics of molecules to reference drugs and historical drug candidates. Gene expression profiling can detect...
